PHARMACEUTICAL companies have been accused of making slight modifications to their drugs to extend a patent life span.
This has resulted in calls for the government to not recognise process methods for patenting, and allowing only molecular patents.
Already a subscriber? Log in.
Subscribe now and receive free sooka plan for 1 month. T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
